Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

অনুরূপ উপাদানগুলি

• Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.
  অনুযায়ী: Kraeber-Bodéré, F, অন্যান্য
  প্রকাশিত: (2012)
• A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors
  অনুযায়ী: Leijen, S, অন্যান্য
  প্রকাশিত: (2011)
• A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.
  অনুযায়ী: Leijen, S, অন্যান্য
  প্রকাশিত: (2011)
• Pharmacokinetics, Pharmacodynamics and Antiviral Efficacy of the MEK Inhibitor Zapnometinib in Animal Models and in Humans
  অনুযায়ী: Julia Koch-Heier, অন্যান্য
  প্রকাশিত: (2022-06-01)
• Pharmacodynamic Monitoring of RO5459072, a Small Molecule Inhibitor of Cathepsin S
  অনুযায়ী: Michel Theron, অন্যান্য
  প্রকাশিত: (2017-07-01)